Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort
- Conditions
- The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agentsMedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Not possible to specify
- Registration Number
- EUCTR2017-001433-74-FR
- Lead Sponsor
- CHU de NIMES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
•Age = 18
•Critically ill patients requiring ICU care
•Receiving systemic therapy of antifungal of interest (triazole, echinocandin, amphotericin) including prophylaxis indication and antifungal therapy started in another unit (wards, operating room) for the same infectious episode
•Availability of suitable intravenous/intra-arterial access to facilitate sample collection
•Written informed consent has been obtained from the patient or their next of kin or the patient has been included in emergency situation
•The patient must be insured or beneficiary of a health insurance plan
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20
•Aged < 18 years of age
•Pregnancy
•Consent not obtained (except in emergency situation)
•Diagnosis with human immunodeficiency virus or hepatitis B or C or tuberculosis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method